← Back to Search


ABBV-552 for Healthy Subjects

Phase 1
Research Sponsored by AbbVie
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Screening 3 weeks
Treatment Varies
Follow Up up to approximately 30 days
Awards & highlights

Study Summary

This trial aims to study how the body processes and eliminates a drug called ABBV-552 in healthy men after they take a single dose by mouth.

Who is the study for?
This trial is for healthy male volunteers. To participate, they must be in good general health at the time of screening.Check my eligibility
What is being tested?
The study is testing ABBV-552 by giving a single oral dose to participants. It aims to assess how the body processes this drug and its safety profile.See study design
What are the potential side effects?
Since this is an early-stage trial focusing on pharmacokinetics, specific side effects are not listed but generally may include reactions at the site of administration, nausea, headache or other common drug-related side effects.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to approximately 30 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to approximately 30 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Amount of ABBV-552 excreted in the feces over the sampling period (Aef)
Amount of ABBV-552 excreted in the urine over the sampling period (Aeu)
Area under the plasma concentration-time curve (AUC) from time 0 to infinite time (AUCinf) of ABBV-552
+9 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: ABBV-552Experimental Treatment1 Intervention
Participants will receive ABBV-552 on Day 1.
First Studied
Drug Approval Stage
How many patients have taken this drug
Completed Phase 1

Find a Location


Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

AbbVieLead Sponsor
956 Previous Clinical Trials
501,342 Total Patients Enrolled
ABBVIE INC.Study DirectorAbbVie
395 Previous Clinical Trials
146,056 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Which individuals meet the criteria for eligibility to take part in this research investigation?

"This study aims to enroll 8 participants aged between 18 and 55 who are currently without any known medical conditions. Specifically, male volunteers in overall good health will be considered during the screening process."

Answered by AI

What are the safety considerations associated with ABBV-552 in individuals?

"Based on the current Phase 1 trial status with limited safety and efficacy data, ABBV-552 received a safety rating of 1 from our team at Power."

Answered by AI

What is the total number of participants being recruited for this research endeavor?

"Yes, information from clinicaltrials.gov indicates that this study is currently seeking participants. It was first listed on 2/21/2024 and last modified on 2/29/2024. The trial aims to enroll 8 patients at a single site."

Answered by AI

Are individuals aged 70 and above being recruited for this research study?

"Recruitment for this study is targeting individuals above 18 years old but below the age of 55."

Answered by AI

Are there any available slots for patients to participate in this research study?

"Indeed, the details on clinicaltrials.gov indicate an ongoing search for suitable candidates for this investigation. The trial was first listed on February 21st, 2024 and most recently revised on February 29th, 2024. Enrollment is open to a total of 8 participants across one designated site."

Answered by AI
~5 spots leftby Apr 2025